Admedus : Shareholder Webinar Presentation

WAYNE PATERSON

Chairman & Interim CEO

Presenting

Mid Year Results and

Business Update

February 2017

This presentation is the property of Admedus Ltd ("Admedus"). No part of this presentation may be reproduced or transmitted in any form or by any means without direct permission in writing from Admedus. This presentation is not and does not constitute an offer, invitation or recommendation to subscribe for, or purchase any security and neither this presentation nor anything contained in it shall form the basis of any contract or commitment.

This presentation does not constitute an offer, solicitation or invitation in any, state or jurisdiction anywhere, or to any person to whom, such an offer or sale would be unlawful. This presentation is not intended as an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the United States or to any person to whom it is unlawful to make such an offer, invitation or solicitation. Reliance should not be placed on the information or opinions contained in this presentation. This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. Any decision to purchase or subscribe for securities in Admedus must be made solely on the basis of the information contained in the public domain and if necessary after seeking appropriate financial and legal advice.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, Admedus and its affiliates and related bodies corporate, and their respective officers, directors, employees and agents disclaim any liability (including, without limitation, any liabilities arising from fault or negligence) for any loss arising from any use of this presentation (or its content) or otherwise arising in connection with it. Admedus' forward-looking statements, intentions, forecasts, prospects, returns, expectations, statements in relation to future matters or other forward looking statement contained in this presentation may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. They are based on a number of estimates, assumptions that are subject to business, scientific, economic and competitive uncertainties and contingencies, with respect to future business decisions, which are subject to change and, in many cases, are outside the control of Admedus and its directors. Neither Admedus nor its directors give any assurance that the forecast performance in the forecasts or any forward-looking statement contained in this presentation will be achieved.

The Year in Numbers…. So far!

• 154% (increase in gross profit over the corresponding period last year) $5.8 million
• 67% (ADAPT® gross margin up from 11% over the corresponding period last year)
• 86 % (sales increase over corresponding period last year) $12.2 million /$6.6 million
• 106% (sales increase for Infusion business over corresponding period last year) $8.7 million
• 59 % (achievement to target at the half way point) $12.2 / $21 million
• 75 % (reduction in sales team in the US ) 3/12
• 50% (reduction in loss after tax compared to corresponding period last year) $5.9 million from $12.8 million
• 100 % (ownership of ADAPT® IP after Regen settlement)
• 51% (ADAPT® sales increase over the corresponding period last year) $3.5 million
• 32% (reduction in SG&A over corresponding period last year)

  The Good the Bad and the Ugly

  The Good

• $1.4 million cost savings in production due to manufacturing efficiencies, moving from "lab scale" to commercial scale production

• Release of the CardioCel® 8 year data

• Completion of significant restructure of the US and EU field force

• Implementation of clear commercial strategy , metrics , and systems (Vision 20/20)

• HSV - 2 +ve ph II interim analysis

• Implementation of corporate values

  The Bad

• Slow roll out of VascuCel® due to resource constraints

  The Ugly

• Identifying the last employees who were in the wrong company and helping them find a new home